Published:  02:52 AM, 04 May 2021

Democrats seek narrow path to rein in cost of medicines

Democrats seek narrow path to rein in cost of medicines

President Joe Biden's call for authorizing Medicare to negotiate lower prescription drug prices has energized Democrats on a politically popular idea they've been pushing for nearly 20 years only to encounter frustration.But they still lack a clear path to enact legislation. That's because a small number of Democrats remain uneasy over government price curbs on pharmaceutical companies.

House Speaker Nancy Pelosi and Senate Majority Leader Chuck Schumer will need every Democratic vote in a narrowly divided Congress. Otherwise Democrats may have to settle for a compromise that stops short of their goal. Or they could take the issue into the 2022 midterm elections. "There is a path," said Rep. Peter Welch, D-Vt., one of Pelosi's lieutenants. "

But there's also a challenge, and the challenge is we've got razor-thin margins." "This is not a done deal," continued Welch. "We've got a president and a speaker, but 'pharma' is very powerful." Pharma is a nickname for the industry and for its main lobbying group, the Pharmaceutical Research and Manufacturers of America, or PhRMA.

The industry thwarted President Donald Trump's multi-pronged efforts to constrain its pricing power. Even though Trump came into office accusing drug makers of "getting away with murder" and vowing he'd put a stop to it, the companies emerged from his term with just a few nicks and cuts.

The industry lobbying group PhRMA is considered one of the most skilled operators in Washington. Its mission: to preserve a clause in the 2003 law that created Medicare's pharmacy benefit barring the government from interfering in price negotiations among drugmakers and insurers. That was enacted before $1,000 pills became old hat.


---AP, Washington 





Leave Your Comments



Latest News


More From World

Go to Home Page »

Site Index The Asian Age